AMPD3 is associated with the malignant characteristics of gastrointestinal stromal tumors

Meihong Wong1, Kohei Funasaka1, Tomohiko Obayashi1

  • 1Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

Oncology Letters
|April 30, 2017
PubMed

Insights

Adenosine monophosphate deaminase 3 (AMPD3) is highly expressed in gastrointestinal stromal tumors (GISTs) and drives their progression. Inhibiting AMPD3 alongside tyrosine kinases may offer a new GIST treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms driven by activating mutations in KIT or PDGFRA.
  • KIT and PDGFRA signaling pathways promote GIST cell proliferation and survival, but precise progression mechanisms remain unclear.

Purpose of the Study:

  • To identify genes associated with GIST progression.
  • To investigate the role of adenosine monophosphate deaminase 3 (AMPD3) in GIST pathogenesis and its relationship with KIT signaling.

Main Methods:

  • Gene expression analysis using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
  • Gene silencing using small interfering RNA (siRNA) targeting KIT and AMPD3 in GIST-T1 cells.
  • Assessment of cell migration, invasion, and sensitivity to imatinib.

Main Results:

  • AMPD3 was found to be highly expressed in GISTs.
  • AMPD3 expression was dependent on KIT expression.
  • AMPD3 depletion suppressed GIST cell migration and invasion and sensitized cells to imatinib.

Conclusions:

  • AMPD3 plays a significant role in GIST progression, mediated by KIT signaling.
  • Combined inhibition of tyrosine kinases and AMPD3 presents a potential therapeutic strategy for GIST treatment.